We are live on ! Find out more
BPMC

Blueprint Medicines
BPMC

Delisted

BPMC was delisted on the 17th of July, 2025.

Back to rankings

175 hedge funds and large institutions have $4B invested in Blueprint Medicines in 2018 Q1 according to their latest regulatory filings, with 31 funds opening new positions, 55 increasing their positions, 63 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

29% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 24

24% more capital invested

Capital invested by funds: $3.23B → $4B (+$771M)

20% more funds holding in top 10

Funds holding in top 10: 10 → 12 (+2)

3% more funds holding

Funds holding: 170 → 175 (+5)

1% more call options, than puts

Call options by funds: $16.4M | Put options by funds: $16.3M

0.15% more ownership

Funds ownership: 99.69% → 99.84% (+0.15%)

13% less repeat investments, than reductions

Existing positions increased: 55 | Existing positions reduced: 63

Holders
175
Holders Change
+5
Holders Change %
+2.94%
% of All Funds
4.01%
Holding in Top 10
12
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+20%
% of All Funds
0.28%
New
31
Increased
55
Reduced
63
Closed
24
Calls
$16.4M
Puts
$16.3M
Net Calls
+$156K
Net Calls Change
-$13.1M

Top Buyers

Rank Fund Capital Flow
1
AG
Artal Group
Luxembourg
+$30.2M
2
VOYA Investment Management
VOYA Investment Management
Georgia
+$25.7M
3
Wellington Management Group
Wellington Management Group
Massachusetts
+$17.9M
4
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$15.9M
5
BlackRock
BlackRock
New York
+$15.2M

Top Sellers

Rank Fund Capital Flow
1
TCM
TimesSquare Capital Management
New York
-$23.2M
2
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
-$16.4M
3
Morgan Stanley
Morgan Stanley
New York
-$13.5M
4
OM
Opaleye Management
Massachusetts
-$11.6M
5
BI
BVF Inc
California
-$9.63M
Name Holding Trade Value Shares
Change 		Change in
Stake
CC
26
Casdin Capital
New York
$31.9M – – –
VOYA Investment Management
27
VOYA Investment Management
Georgia
$29.1M +$25.7M +298,594 +1,580%
DCM
28
Driehaus Capital Management
Illinois
$27.2M +$1.31M +15,229 +5%
Point72 Asset Management
29
Point72 Asset Management
Connecticut
$25.7M -$1.56M -18,052 -6%
Goldman Sachs
30
Goldman Sachs
New York
$25.2M +$9.48M +109,969 +67%
BC
31
Boxer Capital
California
$22.9M – – –
Balyasny Asset Management
32
Balyasny Asset Management
Illinois
$20.9M +$15.9M +184,049 +423%
Jennison Associates
33
Jennison Associates
New York
$19.1M +$2.45M +28,389 +16%
Bank of New York Mellon
34
Bank of New York Mellon
New York
$18.8M +$925K +10,736 +6%
Charles Schwab
35
Charles Schwab
California
$18.2M +$856K +9,933 +5%
Morgan Stanley
36
Morgan Stanley
New York
$17.2M -$13.5M -156,658 -46%
TA
37
Teachers Advisors
New York
$16.2M -$5.81M -67,398 -28%
RSCM
38
Rock Springs Capital Management
Maryland
$14.5M +$970K +11,253 +8%
Deutsche Bank
39
Deutsche Bank
Germany
$14.1M +$3.52M +40,840 +36%
EAM
40
Eventide Asset Management
Massachusetts
$13.8M – – –
GTC
41
Ghost Tree Capital
New York
$11M -$2.59M -30,000 -20%
TCIM
42
TIAA CREF Investment Management
New York
$10.6M -$43.9K -509 -0.4%
Alkeon Capital Management
43
Alkeon Capital Management
New York
$10.2M +$8.76M +101,575 +1,016%
SH
44
Sandia Holdings
Connecticut
$10.1M -$2.24M -25,933 -19%
UBS AM
45
UBS AM
Illinois
$9.9M -$154K -1,784 -2%
DCM
46
DAFNA Capital Management
California
$8.13M -$1.03M -12,000 -12%
California Public Employees Retirement System
47
California Public Employees Retirement System
California
$7.02M -$478K -5,551 -7%
Two Sigma Investments
48
Two Sigma Investments
New York
$6.92M +$2.18M +25,278 +50%
Two Sigma Advisers
49
Two Sigma Advisers
New York
$6.9M -$534K -6,200 -8%
Federated Hermes
50
Federated Hermes
Pennsylvania
$6.87M +$6.46M +74,933 New
1
2
3 4 5

BPMC Hedge Fund Activity: Q1 2018 in Review

175 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Blueprint Medicines (BPMC) for Q1 2018, worth a combined $4B — up 24% from $3.23B a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new BPMC positions and 24 closed out — a net gain of 7 holders — while 55 added to existing stakes and 63 trimmed.

The largest buyer was Artal Group, adding an estimated $30.2M. The largest seller was TimesSquare Capital Management, cutting an estimated $23.2M.

  • 175 institutional investors held Blueprint Medicines (BPMC) as of Q1 2018, up from 170 in Q4 2017.
  • Funds reported $4B of Blueprint Medicines stock for Q1 2018, up 24% quarter-over-quarter.
  • 31 funds opened new Blueprint Medicines positions in Q1 2018 and 24 closed out, a net change of +7 holders.
  • The largest Blueprint Medicines buyer in Q1 2018 was Artal Group, an estimated $30.2M added.
  • The largest Blueprint Medicines seller in Q1 2018 was TimesSquare Capital Management, an estimated $23.2M sold.

Based on aggregated 13F filings for Q1 2018.